The application of quantitative susceptibility mapping and blood and urine cell culture in Wilson's disease

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023410

Enrollment

Unknown

Registered

2019-05-26

Start date

2019-06-01

Completion date

Unknown

Last updated

2019-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wilson’s disease

Interventions

Gold Standard:The main clinical diagnostic criteria: 1) liver disease history, liver disease symptoms or extravertebral system symptoms

2) serum ceruloplasmin was significantly decreased and/or liver copper increased

3) corneal Kayser-Fleischer ring

4) positive family history.

Index test:Quantitative&#32

susceptibility&#32

mapping

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) The patients meet the diagnostic criteria of Wilson's disease, including the newly diagnosed patient and the previously diagnosed patient. (2) The patient with Wilson's disease are beteen 10 years old and 50 years old. (3) The patients or their guardians shall give informed consent and sign the informed consent.

Exclusion criteria

Exclusion criteria: The patients cannot tolerate magnetic resonance examination or have metal implants in the body, which is not suitable for magnetic resonance examination.

Design outcomes

Primary

Measure	Time frame
magnetic susceptibility;SEN, SPE, ROC;	—

Secondary

Measure	Time frame
Copper ion concentration;Iron ion concentration;	—

Countries

China

Contacts

Public ContactXiaoping Wang

Shanghai Tongren Hospital

wangxp@ustc.edu+86 13311986373

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026